Current status of clinical outcome measures in inclusion body myositis: a systematised review
Authors' conclusion
There are inconsistencies in using outcome measures in clinical studies in IBM. The core set measures developed by the IMACS group for other IIMs are not directly applicable to IBM.
Study context
- Population
- Inclusion body myositis (IBM) clinical studies (observational studies, open-label clinical trials and randomised control trials (RCTs))13 observational studies · 17 open-label trials · 15 RCTs
- Outcome
- Outcome measures reported in IBM clinical studies
Methodological detailsIBM scientific interest group under IMACS
- IBM scientific interest group under IMACS
Main finding
As reported in the abstract
Outcome measures used in IBM clinical studies
- Observational studies
- 13
- Open-label clinical trials
- 17
- RCTs
- 15
- Different outcome measures of motor function used in IBM clinical trials
- 12
- RCTs reporting swallowing function (as secondary outcome measure only)
- 3
Original publication
Current status of clinical outcome measures in inclusion body myositis: a systematised review. Clin Exp Rheumatol. Published 16 July 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →